Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05636332 · ClinicalTrials.gov registry record · NA

The Intrepid Clinical Engineering Study

A NA study of Sudden Cardiac Arrest, sponsored by Philips Clinical & Medical Affairs Global.

Completed
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT05636332 is a NA study of Sudden Cardiac Arrest that has completed, run by Philips Clinical & Medical Affairs Global. The registered enrollment target is 60 participants, below the 1,827-participant average among 8 other Sudden Cardiac Arrest trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05636332, a NA study of Sudden Cardiac Arrest, has completed, sponsored by Philips Clinical & Medical Affairs Global.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to collect clinical data to validate a software update for 12-lead electrocardiogram monitoring.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST 12 lead Electrocardiogram

Study Locations (1)

Florida

  • Lehigh Pulmonary Associates, PA (D/B/A Florida Lung & Sleep Associates) - Lehigh Acres

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-10-03
Est. Completion 2022-11-02
Phase NA

What the Registry Record Tells You About NCT05636332

The ClinicalTrials.gov registry entry for NCT05636332 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,827-participant average among 8 other Sudden Cardiac Arrest trials with a reported enrollment target (97% lower). The listed sponsor is Philips Clinical & Medical Affairs Global, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sudden Cardiac Arrest appearing as the primary indexed condition, and to 1 intervention - of which 12 lead Electrocardiogram is the first listed.

NCT05636332 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05636332 about?

NCT05636332 is a clinical study titled "The Intrepid Clinical Engineering Study". The purpose of this research study is to collect clinical data to validate a software update for 12-lead electrocardiogram monitoring.

What is the current status of trial NCT05636332?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2022-10-03. Estimated completion is 2022-11-02.

What conditions does trial NCT05636332 study?

This clinical trial studies the following conditions: Sudden Cardiac Arrest.

What interventions are being tested in trial NCT05636332?

The interventions under investigation include: 12 lead Electrocardiogram (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05636332?

This trial is sponsored by Philips Clinical & Medical Affairs Global, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05636332 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sudden Cardiac Arrest

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.